SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Pseudo Biologist who wrote (16764)3/7/1998 11:54:00 PM
From: Henry Niman  Respond to of 32384
 
PB, The Keystone and Lake Tahoe reports were on a small molecule that mimics G-CSF with extreme specificity. The generation of analogs and screening should pave the wave for a whole new arsenal of drugs. Some may laugh, but I suspect that this application impacted the SBH/GLX deal. There are plenty of known targets and rationale analogs can be made very quickly and cheaply. The little boys in the candy store have already sampled the goods. They don't have to keep shopping.



To: Pseudo Biologist who wrote (16764)3/7/1998 11:57:00 PM
From: Hippieslayer  Read Replies (1) | Respond to of 32384
 
Then what the significance is a more "direct path" to treating a certian disease with a drug or molecule that, in theory, will be less costly to make and easier to administer. Would you say that is correct?

I am familiar with AMGN, the two drug wonder biopharma in Thousand Oaks, Ca. Right up the 405; one of the busiest freeways in America. I believe Neupogen generated roughly 800 million dollars for AMGN last year.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News